Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)

Completed · Phase 1/Phase 2

Conditions studied: HIV-1 Infection

In brief

The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART. The investigators wanted to learn whether sirolimus decreases inflammation and immune activation in the body; whether sirolimus changes the level of HIV in the participants' blood; and how sirolimus interacts with ART in the blood. Sirolimus is approved by the Food and Drug Administration (FDA) to prevent organ rejection in patients aged 13 years and older receiving kidney transplants. Sirolimus had also been used for the prevention of complications after stem cell transplants and as a treatment for certain kinds of cancers in HIV-infected patients.

Key facts

Study ID

NCT02440789

Run by

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

People needed

32

Starts

2015-12-21

Expected to finish

2018-02-01

Last updated by the study team

2021-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 infection
• On continuous ART for ≥24 months prior to study entry.
• CD4+ cell count ≥350 cells/mm\^3
• Plasma HIV-1 RNA below the level of quantification for ≥24 months.
• White blood cell (WBC) ≥3000/mm\^3
• Platelet count ≥125,000/mm\^3
• Absolute neutrophil count (ANC) >1300/mm\^3
• Aspartate aminotransferase (AST) <1.25 x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) <1.25 x ULN
• Calculated creatinine clearance (CrCl) ≥60 mL/min
• Fasting or non-fasting triglyceride level ≤350 mg/dL
• Fasting or non-fasting LDL <160 mg/dL
• Urine protein to urine creatinine ratio ≤1 g/g from random urine collection

You may not qualify if…

• Serious illness requiring systemic treatment and/or hospitalization
• Documentation of any CDC Category C AIDS-indicator condition or oropharyngeal candidiasis (thrush)
• Intended modification of ART during the study.
• Latent tuberculosis (TB) infection
• TB disease within 48 weeks prior to study entry requiring treatment.
• History of active hepatitis B (HBV) infection.
• Hepatitis C virus (HCV) RNA-positive
• Previous myelodysplasia syndrome, lymphoproliferative disease, lung disease, malignancies, congestive heart failure, life-threatening fungal infection or herpes-zoster/varicella-zoster viral infection requiring treatment.
• Detectable Epstein-Barr virus (EBV) in blood
• Active infection other than HIV that required receipt of systemic antibiotic therapy by intravenous infusion
• History of major hypersensitivity reaction to macrolide drugs including angioedema, anaphylaxis, drug-induced dermatitis, or hypersensitivity vasculitis.
• Currently pregnant or breastfeeding, or planning to become pregnant prior to or during the study.
• Use of immunomodulators (eg, interleukins, interferons, and cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy.
• Active drug or alcohol use or dependence
• Vaccination within 14 days prior to study entry.
• On or planned to change to a PI-based ART or cobicistat-boosted regimen
• Anti-human papillomavirus (HPV) therapies

Where it is running

• 801 University of California, San Francisco HIV/AIDS CRS — San Francisco, California, United States
• Whitman Walker Health CRS (31791) — Washington D.C., District of Columbia, United States
• Univ. of Miami AIDS CRS (901) — Miami, Florida, United States
• The Ponce de Leon Center CRS (5802) — Atlanta, Georgia, United States
• Washington University CRS (2101) — St Louis, Missouri, United States
• Weill Cornell Uptown CRS (7803) — New York, New York, United States
• 31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS — Rochester, New York, United States
• Univ. of Cincinnati CRS (2401) — Cincinnati, Ohio, United States
• Houston AIDS Research Team CRS (31473) — Houston, Texas, United States
• University of Washington AIDS CRS (1401) — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.